vs
Side-by-side financial comparison of EXELIXIS, INC. (EXEL) and Hilltop Holdings Inc. (HTH). Click either name above to swap in a different company.
EXELIXIS, INC. is the larger business by last-quarter revenue ($598.7M vs $300.5M, roughly 2.0× Hilltop Holdings Inc.). EXELIXIS, INC. runs the higher net margin — 40.8% vs 13.0%, a 27.9% gap on every dollar of revenue. Over the past eight quarters, EXELIXIS, INC.'s revenue compounded faster (18.7% CAGR vs 0.6%).
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
Hilltop Holdings Inc. is a financial holding company based in Dallas, Texas. It offers financial products and banking services through three primary subsidiaries: PlainsCapital Bank, PrimeLending, and HilltopSecurities.
EXEL vs HTH — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $598.7M | $300.5M |
| Net Profit | $244.5M | $39.0M |
| Gross Margin | 95.6% | — |
| Operating Margin | 39.3% | — |
| Net Margin | 40.8% | 13.0% |
| Revenue YoY | 5.6% | — |
| Net Profit YoY | 74.8% | -12.4% |
| EPS (diluted) | $0.89 | $0.64 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $598.7M | $300.5M | ||
| Q4 25 | $597.8M | $329.9M | ||
| Q3 25 | $568.3M | $330.2M | ||
| Q2 25 | $555.4M | $303.3M | ||
| Q1 25 | $566.8M | $318.5M | ||
| Q4 24 | — | $301.1M | ||
| Q3 24 | $539.5M | $305.5M | ||
| Q2 24 | $637.2M | $297.0M |
| Q1 26 | $244.5M | $39.0M | ||
| Q4 25 | $193.6M | $41.6M | ||
| Q3 25 | $184.8M | $45.8M | ||
| Q2 25 | $159.6M | $36.1M | ||
| Q1 25 | $139.9M | $42.1M | ||
| Q4 24 | — | $35.5M | ||
| Q3 24 | $118.0M | $29.7M | ||
| Q2 24 | $226.1M | $20.3M |
| Q1 26 | 95.6% | — | ||
| Q4 25 | 96.9% | — | ||
| Q3 25 | 96.6% | — | ||
| Q2 25 | 96.5% | — | ||
| Q1 25 | 96.5% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 96.8% | — | ||
| Q2 24 | 97.2% | — |
| Q1 26 | 39.3% | — | ||
| Q4 25 | 39.6% | 16.1% | ||
| Q3 25 | 37.6% | 18.4% | ||
| Q2 25 | 33.6% | 16.3% | ||
| Q1 25 | 28.8% | 18.1% | ||
| Q4 24 | — | 14.7% | ||
| Q3 24 | 25.2% | 13.9% | ||
| Q2 24 | 43.3% | 10.0% |
| Q1 26 | 40.8% | 13.0% | ||
| Q4 25 | 32.4% | 12.6% | ||
| Q3 25 | 32.5% | 13.9% | ||
| Q2 25 | 28.7% | 11.9% | ||
| Q1 25 | 24.7% | 13.2% | ||
| Q4 24 | — | 11.8% | ||
| Q3 24 | 21.9% | 9.7% | ||
| Q2 24 | 35.5% | 6.8% |
| Q1 26 | $0.89 | $0.64 | ||
| Q4 25 | $0.69 | $0.68 | ||
| Q3 25 | $0.65 | $0.74 | ||
| Q2 25 | $0.55 | $0.57 | ||
| Q1 25 | $0.47 | $0.65 | ||
| Q4 24 | — | $0.55 | ||
| Q3 24 | $0.40 | $0.46 | ||
| Q2 24 | $0.77 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.1B | — |
| Total DebtLower is stronger | — | $990.8M |
| Stockholders' EquityBook value | $2.2B | $2.2B |
| Total Assets | $2.8B | $15.7B |
| Debt / EquityLower = less leverage | — | 0.46× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.1B | — | ||
| Q4 25 | $988.5M | — | ||
| Q3 25 | $791.1M | — | ||
| Q2 25 | $1.0B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $1.2B | — | ||
| Q2 24 | $1.0B | — |
| Q1 26 | — | $990.8M | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $2.2B | $2.2B | ||
| Q4 25 | $2.2B | $2.2B | ||
| Q3 25 | $2.0B | $2.2B | ||
| Q2 25 | $2.1B | $2.2B | ||
| Q1 25 | $2.2B | $2.2B | ||
| Q4 24 | — | $2.2B | ||
| Q3 24 | $2.3B | $2.2B | ||
| Q2 24 | $2.1B | $2.1B |
| Q1 26 | $2.8B | $15.7B | ||
| Q4 25 | $2.8B | $15.8B | ||
| Q3 25 | $2.7B | $15.6B | ||
| Q2 25 | $2.8B | $15.4B | ||
| Q1 25 | $2.9B | $15.8B | ||
| Q4 24 | — | $16.3B | ||
| Q3 24 | $3.0B | $15.9B | ||
| Q2 24 | $2.8B | $15.6B |
| Q1 26 | — | 0.46× | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $333.5M | — |
| Free Cash FlowOCF − Capex | $332.4M | — |
| FCF MarginFCF / Revenue | 55.5% | — |
| Capex IntensityCapex / Revenue | 0.2% | — |
| Cash ConversionOCF / Net Profit | 1.36× | — |
| TTM Free Cash FlowTrailing 4 quarters | $875.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $333.5M | — | ||
| Q4 25 | $290.3M | $-38.7M | ||
| Q3 25 | $49.0M | $273.0M | ||
| Q2 25 | $211.4M | $-234.6M | ||
| Q1 25 | $240.3M | $5.8M | ||
| Q4 24 | — | $273.9M | ||
| Q3 24 | $271.3M | $515.6M | ||
| Q2 24 | $119.5M | $-435.3M |
| Q1 26 | $332.4M | — | ||
| Q4 25 | $288.8M | $-55.5M | ||
| Q3 25 | $46.2M | $271.0M | ||
| Q2 25 | $208.5M | $-234.6M | ||
| Q1 25 | $236.3M | $5.0M | ||
| Q4 24 | — | $266.8M | ||
| Q3 24 | $263.1M | $513.8M | ||
| Q2 24 | $113.0M | $-437.3M |
| Q1 26 | 55.5% | — | ||
| Q4 25 | 48.3% | -16.8% | ||
| Q3 25 | 8.1% | 82.1% | ||
| Q2 25 | 37.5% | -77.4% | ||
| Q1 25 | 41.7% | 1.6% | ||
| Q4 24 | — | 88.6% | ||
| Q3 24 | 48.8% | 168.2% | ||
| Q2 24 | 17.7% | -147.2% |
| Q1 26 | 0.2% | — | ||
| Q4 25 | 0.2% | 5.1% | ||
| Q3 25 | 0.5% | 0.6% | ||
| Q2 25 | 0.5% | 0.0% | ||
| Q1 25 | 0.7% | 0.3% | ||
| Q4 24 | — | 2.4% | ||
| Q3 24 | 1.5% | 0.6% | ||
| Q2 24 | 1.0% | 0.7% |
| Q1 26 | 1.36× | — | ||
| Q4 25 | 1.50× | -0.93× | ||
| Q3 25 | 0.27× | 5.96× | ||
| Q2 25 | 1.32× | -6.50× | ||
| Q1 25 | 1.72× | 0.14× | ||
| Q4 24 | — | 7.71× | ||
| Q3 24 | 2.30× | 17.36× | ||
| Q2 24 | 0.53× | -21.41× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EXEL
| Cabometyx | $544.7M | 91% |
| Collaboration | $52.1M | 9% |
| Collaborative Arrangementwith Takeda | $5.9M | 1% |
| Cometriq | $1.8M | 0% |
HTH
| Noninterest Income | $188.4M | 63% |
| Net Interest Income | $112.1M | 37% |
